To read the full story, subscribe or sign in.

Threshold's Stock Slammed on Pancreatic Cancer Drug Data

Sep. 18, 2012

Threshold Pharmaceuticals Inc. saw its shares fall 19.7 percent Monday, following release of an update to its Phase IIb trial of TH-302 in pancreatic cancer.

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for July 10, 2026.

Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

BioWorld

News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...

FENS 2026: Shedding light on the sheddome

BioWorld

At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...

FENS 2026: Next-gen biologics take on brain disease

BioWorld

Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...

Liver with hepatitis viruses, blood cells

Recombinant vaccine inhibits HBV-associated HCC growth

BioWorld Science

Chronic liver disease and hepatocellular carcinoma (HCC) associated with chronic hepatitis B virus (HBV) are serious health problems in highly endemic areas....